TXGHealthcare · Medical Devices

TXG Stock Forecast: 10X Genomics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026

$77

−0.48% on the day

The 18 Wall Street analysts covering 10X Genomics, Inc. hold a median 12-month price target of $50 — -34.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 19 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap

$10.0B

Ticker Nerd rank

94 / 100

Median analyst target

$50

Analysts covering

Revenue$151.0M−12.6% y/y

Operating income−$23.0M

Net income−$17.9M

Free cash flow$15.4M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+11.7%

+37.7%

YTD

+369.7%

+477.2%

From 52W high

−0.5%

From 52W low

+575.5%

$11

$77

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

TXG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 10X Genomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026

94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum

Accruals

Quality

Revisions

Value

Issuance

Growth

Volatility

Size

Momentum (99): The shares have been drifting up relative to others.

Volatility (47): The share price moves around a lot.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TXG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TXG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts

6 Buy12 Hold0 Sell

Low $40Median $50High $70

The green dot is the last close — the median target sits −34.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

Date	Firm	Action	Rating	Target
9 Sept 2026	UBS	Maintains	Neutral	$20 → $68
1 Sept 2026	RBC Capital	Initiates	Sector Perform	—
1 Sept 2026	RBC Capital	Initiates	Sector Perform	$70
12 Aug 2026	Stephens & Co.	Maintains	Overweight	—
12 Aug 2026	Stephens & Co.	Maintains	Overweight	$50 → $65
10 Aug 2026	Canaccord Genuity	Maintains	Buy	$50 → $60
10 Aug 2026	Canaccord Genuity	Maintains	Buy	—
10 Aug 2026	Piper Sandler	Maintains	Neutral	$42 → $47
10 Aug 2026	Piper Sandler	Maintains	Neutral	—
7 Aug 2026	Citigroup	Maintains	Neutral	$45 → $50
7 Aug 2026	Citigroup	Maintains	Neutral	—
7 Aug 2026	Morgan Stanley	Maintains	Equal-Weight	$37 → $40
7 Aug 2026	Morgan Stanley	Maintains	Equal-Weight	—
17 July 2026	Leerink Partners	Maintains	Market Perform	—
17 July 2026	Leerink Partners	Maintains	Market Perform	$23 → $40
14 July 2026	Canaccord Genuity	Maintains	Buy	—
14 July 2026	Canaccord Genuity	Maintains	Buy	$32 → $50
9 July 2026	Morgan Stanley	Maintains	Equal-Weight	$22 → $37
9 July 2026	Morgan Stanley	Maintains	Equal-Weight	—
8 July 2026	Citigroup	Maintains	Neutral	$24 → $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TXG appears on the weeks it earns a place.

Performance

TXG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, 10X Genomics, Inc. returned +477.2% against +16.3% for the S&P 500, dividends included.

TXG vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TXG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

10X Genomics, Inc. (TXG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −217.7×
Price / sales: 16.1×
Price / book: 12.1×
EV / EBITDA: −231.9×

Growth & margins

Revenue growth (YoY): −12.7%
Earnings growth (YoY): −12.6%
Gross margin: 74.5%
Operating margin: −15.2%
Net margin: −12.2%

Returns & dividend

Return on equity: −9.4%
Return on assets: −5.0%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

10X Genomics, Inc. (TXG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

10X Genomics, Inc. has a market value of $10.0B and an enterprise value of $9.6B.
Revenue in the twelve months to 30 June 2026: $616.9M. The latest quarter shrank 12.7% year on year.
Net income over the same four quarters: −$75.1M, a −12.2% net margin.
Diluted earnings per share, trailing twelve months: $−0.59.
Free cash flow in the twelve months to 30 June 2026: $121.4M.
Shares outstanding: 130.3M.
Trailing P/E: −217.7×; forward P/E: 374.8× — the forward figure prices analyst consensus estimates, not reported earnings.
10X Genomics, Inc. employs 1,178 people — $524K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

TXG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
TXG10X Genomics, Inc.	$10.0B	94
GMEDGlobus Medical, Inc.	$9.9B	96
BIOBio-Rad Laboratories, Inc.	$10.1B	90
PODDInsulet Corp.	$9.7B	89
GKOSGlaukos Corp.	$9.7B	92
BRKRBruker Corp.	$9.3B	87
PENPenumbra, Inc.	$12.5B	75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 10X Genomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TXG news & analysis

Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research

PRNewsWire · 10 Sept 2026positive

Lunit announced that 10x Genomics will integrate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. The collaboration combines 10x Genomics' spatial biology technologies with Lunit's AI-enabled H&E pathology analysis for oncology clinical research.

Why it matters — The collaboration expands 10x Genomics' oncology biomarker discovery offering by pairing its spatial biology technologies with AI-driven pathology analysis.

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

Zacks Investment Research · 3 Sept 2026neutral

Tenx Genomics shares have rallied 84% over the past three months, supported by growth in consumables, demand for its Atera product, and higher guidance. However, weak instrument sales and elevated valuation are cited as concerns.

Why it matters — A TXG watcher would care because the article highlights both the drivers behind the recent stock surge and the countervailing risks that could affect the company's outlook.

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

Benzinga · 1 Sept 2026positive

Benzinga reports that Moderna and Merck's positive Phase 3 results for a personalized mRNA cancer vaccine could serve as a new catalyst for the biotech sector beyond GLP-1 drugs, potentially reviving investor interest in genomics, immunotherapy, and precision medicine ETFs.

Why it matters — Renewed investor attention on genomics and precision medicine as a result of cancer vaccine progress could translate into broader sector interest that TXG watchers would track.

TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences

Zacks Investment Research · 31 Aug 2026positive

10x Genomics won a $4.8M patent verdict against Parse Biosciences, strengthening its intellectual property position as it pursues additional damages and a U.S. injunction. The stock traded down despite the victory.

Why it matters — The patent win reinforces 10x Genomics' intellectual property position, which is central to protecting its competitive standing in the genomics market.

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

PRNewsWire · 28 Aug 2026positive

A jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, a subsidiary of Qiagen, willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025, and rejected Parse's challenge to the patents' validity.

Why it matters — The favorable jury verdict supports the intellectual property position of Scale Biosciences, a 10x Genomics subsidiary, which may be relevant to 10x Genomics' competitive standing in the single-cell and Spatial genomics market.

FAQ

Frequently asked questions about TXG stock

What is the TXG stock price forecast for 2026-2027?

The 18 Wall Street analysts covering 10X Genomics, Inc. have a median 12-month price target of $50, with estimates ranging from $40 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TXG stock a buy right now?

Of the 18 analysts covering 10X Genomics, Inc., 6 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 10X Genomics, Inc. 94 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TXG?

As at 19 Sept 2026, 10X Genomics, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will TXG stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies -34.7% from the last close, and Ticker Nerd's factor model ranks 10X Genomics, Inc. 94 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TXG stock forecast for 2030?

No analyst covering 10X Genomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TXG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $70 over the next 12 months.

How has TXG stock performed over the past year?

10X Genomics, Inc. returned +477.2% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does 10X Genomics, Inc. do?

10x Genomics Inc. Class A Common Stock represents ownership in 10x Genomics, a life science technology company focused on products that help researchers study biology at high resolution.

What is the latest news on TXG?

The most recent item we track (PRNewsWire, 10 Sept 2026): "Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research". Lunit announced that 10x Genomics will integrate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. The collaboration combines 10x Genomics' spatial biology technologies with Lunit's AI-enabled H&E pathology analysis for oncology clinical research.

Company

About 10X Genomics, Inc.

10x Genomics Inc. Class A Common Stock represents ownership in 10x Genomics, a life science technology company focused on products that help researchers study biology at high resolution. The company develops integrated instruments, consumables, and software used for single-cell and spatial biology workflows, supporting applications such as gene expression analysis, immune profiling, chromatin accessibility, spatial transcriptomics, and in situ exploration of tissue biology. Its main product families include the Chromium platform, the Chromium X series, Visium, and Xenium, which are used by academic researchers, pharmaceutical companies, biotechnology firms, and other scientific organizations. 10x Genomics serves global markets across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. The stock is commonly associated with the broader life sciences tools and services sector, where the company plays a specialized role in enabling advanced biological research and data generation.

CEO Dr. Serge Saxonov Ph.D. · 1,178 employees · United States · https://www.10xgenomics.com